Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function
Publication Year: 2025 Source: Am J Physiol Gastrointest Liver Physiol PMID: 40569574 DOI: 10.1152/ajpgi.00086.2025
Background: Epithelial cell death and compromised barrier function are key features of inflammatory bowel disease (IBD) pathogenesis. Previous studies suggest the nuclear bile acid receptor, farnesoid X receptor (FXR), to promote intestinal barrier function and protect against inflammation. Here, we investigated potential mechanisms involved. Methods: T(84) cell monolayers were treated …
It takes 2 to inflame: microbiota and genotype shape CGD IBD
Publication Year: 2025 Source: Blood PMID: 40569644 DOI: 10.1182/blood.2025029443
No Abstract
Therapeutic potential of NRF2 activating drug RTA-408 in suppressing T cell effector responses and inflammatory bowel disease
Publication Year: 2025 Source: J Immunol PMID: 40570091 DOI: 10.1093/jimmun/vkaf117
RTA-408, also known as Omaveloxolone, is an FDA-approved drug for treating Friedrich's Ataxia, a neurological disorder. It is a triterpenoid compound that activates nuclear factor erythroid 2-related factor 2 (NRF2), a key regulator of cellular redox balance. In this study, we explored the impact of RTA-408 on T cells and …
A caged drug enables precision delivery
Publication Year: 2025 Source: Science PMID: 40570132
"GlycoCaging" uses gut bacteria to activate drugs for inflammatory bowel disease.
Oxidative stress and chronic inflammation as partners in crime in interstitial cystitis/bladder pain syndrome
Publication Year: 2025 Source: J Innate Immun PMID: 40570823
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic inflammatory disease of the urinary bladder, characterized by chronic pain, increased urinary frequency, urgency, and nocturia. Currently, no therapeutic option consistently provides long-term relief for all IC/BPS patients, likely due to the largely unknown mechanisms underlying the disease's development and progression. IC/BPS …
A comprehensive review of small bowel length measurement: methodological challenges and variability factors
Publication Year: 2025 Source: Prog Biomed Eng (Bristol) PMID: 40570893
The measurement of small bowel length (SBL) is crucial in clinical contexts such as surgical planning, assessment of nutritional absorption and management of conditions like short bowel syndrome (SBS) and Crohn's disease (CD). However, the literature reports substantial variations in measurements of average SBL, influenced by a multitude of methodological …
Refining Predictive Models in Preclinical IBD: Need for Expanded Validation and Clinical Translation
Publication Year: 2025 Source: Gastroenterology PMID: 40570978 DOI: 10.1053/j.gastro.2025.04.042
No Abstract
Histopathologic Evaluation and Single-cell Spatial Transcriptomics of the Colon Reveal Cellular and Molecular Abnormalities Linked to J-Pouch Failure in Patients with Inflammatory Bowel Disease
Publication Year: 2025 Source: Cell Mol Gastroenterol Hepatol PMID: 40571096
BACKGROUND & AIMS: Total abdominal colectomy (TAC) with a staged ileal pouch-anal anastomosis (IPAA) is a common surgical treatment for ulcerative colitis (UC). However, a significant percentage of patients experience pouch failure, leading to morbidity. This retrospective case-control study identified histopathologic features of the TAC specimen associated with pouch failure …
Upadacitinib in Mother with Inflammatory Bowel Disease: Placental Transfer and Breast milk Excretion
Publication Year: 2025 Source: Clin Gastroenterol Hepatol PMID: 40571170 DOI: 10.1016/j.cgh.2025.06.007
No Abstract
Novel aryl hydrocarbon receptor agonists as potential anti-inflammatory therapeutics: Identification and validation through drug repurposing
Publication Year: 2025 Source: Biochem Pharmacol PMID: 40571216 DOI: 10.1016/j.bcp.2025.117066
The aryl hydrocarbon receptor (AhR) was shown to be an important regulator of inflammatory processes at epithelial barriers, and is thus considered a therapeutic target for several chronic inflammatory diseases, such as inflammatory bowel disease. We aimed to identify and validate new AhR agonists that sustainably attenuate intestinal inflammation. Using …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide